|Articles|January 29, 2015

Pharma 2015: Industry in Flux

Pharma is still a 21st Century growth industry, but investment dynamics no longer favor organic growth. Check out our strategic outlook infographic.

Newsletter

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

Subscribe Now!

Related Content

Moderna Takes Out $1.5 Billion Loan as Part of Three-Year Business Plan

ByNicholas Jacobus

November 24th 2025

Image Credit: Adobe Stock Images/OlegKachura. From a distance, the first 15 CNPV awards look like a policy experiment in speeding up reviews. Up close, they are something more: a sorting mechanism that rewards early movers in operating model transformation, not just drug discovery.

Winners & Losers: What the First FDA Commissioner’s National Priority Vouchers Tell Us About Early Movers vs. Late Movers

ByThani Jambulingam, PhD

November 19th 2025

Image Credit: Adobe Stock Images/gguy. The CNPV marks a turning point for the pharmaceutical industry. Speed is no longer something companies can buy, it’s something they must build.

How the FDA Commissioner’s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy

ByThani Jambulingam, PhD

November 18th 2025

Image Credit: Adobe Stock Images/kittyfly. Novo Nordisk sign on building, Danish pharmaceutical healthcare giant, production innovative drugs, obesity treatment Ozempic, pharmaceutical company innovation

Novo Nordisk’s New Board: A Shift Back to Science & Operations But a Step Away From Commercial Priorities?

ByThani Jambulingam, PhD

November 17th 2025

The 49th State: Q&A with Mark Mikhael

ByMike Hollan

November 17th 2025

Pharma 2015: Industry in Flux

Newsletter

Related Content

Moderna Takes Out $1.5 Billion Loan as Part of Three-Year Business Plan

Winners & Losers: What the First FDA Commissioner’s National Priority Vouchers Tell Us About Early Movers vs. Late Movers

How the FDA Commissioner’s National Priority Vouchers Reshape Manufacturing, Pricing & Global Strategy

Novo Nordisk’s New Board: A Shift Back to Science & Operations But a Step Away From Commercial Priorities?

The 49th State: Q&A with Mark Mikhael

Trending on PharmExec

Report: Richard Pazdur Out as Director of CDER

Pharmaceutical Commercialization: A 2026 Outlook Personalization and Precision Will Define a New Year in Pharma

Lilly Reduces Price of Zepbound Single-Dose Vials for Self-Pay Patients

Regeneron Announces $150 Million Collaboration with Tessera Therapeutics to Develop Gene Editing Therapy

FDA Announces Agency-Wide Deployment of Agentic AI Tools